טוען...
CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought
CDK4/6 inhibitors are among a new generation of therapeutics. Building upon the striking success of the combination of CDK4/6 inhibitors and the hormone receptor antagonist letrozole in breast cancer, many other combinations have recently entered clinical trials in multiple diseases. To achieve maxi...
שמור ב:
| הוצא לאור ב: | Cancer Cell |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6039233/ https://ncbi.nlm.nih.gov/pubmed/29731395 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2018.03.023 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|